WallStreetZenWallStreetZen

NASDAQ: STRO
Sutro Biopharma Inc Stock

$3.46-0.39 (-10.13%)
Updated Jun 14, 2024
STRO Price
$3.46
Fair Value Price
N/A
Market Cap
$283.01M
52 Week Low
$2.01
52 Week High
$6.13
P/E
-1.84x
P/B
2.89x
P/S
2.25x
PEG
N/A
Dividend Yield
N/A
Revenue
$154.07M
Earnings
-$114.96M
Gross Margin
100%
Operating Margin
-56.31%
Profit Margin
-74.6%
Debt to Equity
3.12
Operating Cash Flow
-$115M
Beta
1.44
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

STRO Overview

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

STRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STRO is good value based on its book value relative to its share price (2.89x), compared to the US Biotechnology industry average (6.25x)
P/B vs Industry Valuation
STRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STRO due diligence checks available for Premium users.

Be the first to know about important STRO news, forecast changes, insider trades & much more!

STRO News

Valuation

STRO fair value

Fair Value of STRO stock based on Discounted Cash Flow (DCF)
Price
$3.46
Fair Value
-$0.14
Undervalued by
2,633.52%
STRO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

STRO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.84x
Industry
-10.23x
Market
30.51x

STRO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.89x
Industry
6.25x
STRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

STRO's financial health

Profit margin

Revenue
$13.0M
Net Income
-$58.2M
Profit Margin
-447.5%
STRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
STRO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$403.4M
Liabilities
$305.4M
Debt to equity
3.12
STRO's short-term assets ($354.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STRO's short-term assets ($354.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$64.7M
Investing
$64.1M
Financing
-$3.4M
STRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

STRO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
STRO$283.01M-10.13%-1.84x2.89x
OBIO$285.23M+1.92%-5.39x4.99x
MGNX$279.97M-4.49%-11.76x2.64x
MGTX$288.74M-2.60%-3.84x2.37x
ICU$290.36M+9.07%-3.85x-64.92x

Sutro Biopharma Stock FAQ

What is Sutro Biopharma's quote symbol?

(NASDAQ: STRO) Sutro Biopharma trades on the NASDAQ under the ticker symbol STRO. Sutro Biopharma stock quotes can also be displayed as NASDAQ: STRO.

If you're new to stock investing, here's how to buy Sutro Biopharma stock.

What is the 52 week high and low for Sutro Biopharma (NASDAQ: STRO)?

(NASDAQ: STRO) Sutro Biopharma's 52-week high was $6.13, and its 52-week low was $2.01. It is currently -43.56% from its 52-week high and 72.57% from its 52-week low.

How much is Sutro Biopharma stock worth today?

(NASDAQ: STRO) Sutro Biopharma currently has 81,794,334 outstanding shares. With Sutro Biopharma stock trading at $3.46 per share, the total value of Sutro Biopharma stock (market capitalization) is $283.01M.

Sutro Biopharma stock was originally listed at a price of $15.20 in Sep 27, 2018. If you had invested in Sutro Biopharma stock at $15.20, your return over the last 5 years would have been -77.24%, for an annualized return of -25.62% (not including any dividends or dividend reinvestments).

How much is Sutro Biopharma's stock price per share?

(NASDAQ: STRO) Sutro Biopharma stock price per share is $3.46 today (as of Jun 14, 2024).

What is Sutro Biopharma's Market Cap?

(NASDAQ: STRO) Sutro Biopharma's market cap is $283.01M, as of Jun 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Sutro Biopharma's market cap is calculated by multiplying STRO's current stock price of $3.46 by STRO's total outstanding shares of 81,794,334.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.